ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.K. Academics Get Drug Firm Compounds

by Alex Scott
December 15, 2014 | APPEARED IN VOLUME 92, ISSUE 50

Seven major pharmaceutical companies have given a total of 68 shelved compounds to academic researchers as part of a deal brokered by the U.K.’s Medical Research Council. U.K. scientists can apply for MRC funding to use the compounds in medical studies. The compounds were developed for treating diseases including cancer, narcolepsy, and diabetes but were rejected, often for lack of effectiveness. The seven companies are AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly & Co., Pfizer, Takeda, and UCB. MRC hopes to add more compounds as its scheme progresses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment